FDA Approved: ONPATTRO — Supplemental Application (Alnylam Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ONPATTRO (patisiran) submitted by Alnylam Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy

Drugs mentioned

• Onpattro (patisiran)

Snippet

SUPPL AP for ONPATTRO (PATISIRAN)